GH Secretagogue Comparison: Ipamorelin, CJC-1295, Sermorelin and GHRP-6 for Research (UK 2026)

GH secretagogues are among the most widely researched peptide classes — and the most frequently confused. Ipamorelin, CJC-1295, sermorelin, and GHRP-6 all stimulate growth hormone release but through fundamentally different mechanisms, with different receptor targets, different GH pulse profiles, different selectivity, and different appropriate research applications. This guide provides a systematic comparison to inform correct research tool selection for GH axis biology.

Receptor Targets: The Fundamental Divide

The most important mechanistic distinction is receptor class:

GHRH receptor agonists — Sermorelin and CJC-1295 both bind the GHRH receptor (GHRHR) on pituitary somatotrophs, activating Gs/cAMP/PKA signalling to stimulate GH synthesis and secretion. They mimic the hypothalamic GHRH pulse that normally initiates each GH secretory episode. Their GH-stimulating activity is entirely pituitary-dependent — if the pituitary is absent or non-functional, GHRHR agonists produce no GH response.

GHS-R1a (ghrelin receptor) agonists — Ipamorelin and GHRP-6 both bind GHS-R1a — the ghrelin receptor — activating Gq/IP3/calcium signalling in somatotrophs. They mimic the ghrelin signal that amplifies and co-drives GH secretion alongside GHRH. GHS-R1a is expressed in both pituitary (GH secretagogue effect) and hypothalamus (appetite, sleep effects). These two receptor classes are synergistic: combining a GHRHR agonist with a GHS-R1a agonist produces substantially more GH than either alone.

Half-Life and GH Pulse Profile

Half-life determines the GH pulse profile produced and is arguably the most important practical distinction for research design:

Sermorelin: Half-life approximately 10–20 minutes after subcutaneous injection. Produces a single GH pulse per injection — physiologically faithful to the endogenous GHRH/GH pulse. GH returns to near-baseline within 1–2 hours. Appropriate for research studying pulsatile GH physiology, GH stimulation testing, or designs requiring discrete GH pulses.

CJC-1295 (with DAC): Half-life approximately 6–8 days due to albumin-binding via DAC technology. Produces sustained “GH bleed” — elevated baseline GH and IGF-1 for 5–7 days from a single injection. Not pulsatile in the physiological sense. Appropriate for chronic GH axis activation studies where sustained elevation is the experimental variable and infrequent dosing is advantageous.

Ipamorelin: Half-life approximately 2 hours after subcutaneous injection. Produces a single, clean GH pulse per injection with peak within 30–60 minutes and return to baseline within 3–4 hours. Minimal cortisol co-stimulation. Appropriate for research requiring clean GH pulses without off-target hormonal effects.

GHRP-6: Half-life approximately 15–60 minutes. Produces a rapid, potent GH pulse but also co-stimulates cortisol, prolactin, and appetite (through hypothalamic GHS-R1a). Less selective than Ipamorelin. Appropriate for research specifically studying ghrelin-axis biology including appetite, gastric motility, and the full GHS-R1a pharmacological profile.

Selectivity: Cortisol and Prolactin Co-Stimulation

This distinction matters enormously for research design:

Ipamorelin: Extremely selective — produces minimal cortisol or prolactin co-stimulation at GH-effective doses. The “clean” GH secretagogue. Studies of GH effects on muscle, metabolism, or recovery are not confounded by cortisol’s catabolic and immune effects.

GHRP-6: Less selective — produces significant cortisol co-stimulation (approximately 20–50% above baseline at GH-effective doses) through activation of the HPA axis via GHS-R1a in the hypothalamus. Also stimulates prolactin. This limits GHRP-6 for studies where cortisol confounding must be avoided.

Sermorelin and CJC-1295: GHRHR agonists — they do not activate GHS-R1a and therefore do not directly stimulate cortisol or appetite. Cortisol effects are minimal and secondary (GH can mildly elevate cortisol through IGF-1 feedback).

Combination Protocols

GHRHR agonists and GHS-R1a agonists are synergistic — the combination of a GHRHR agonist with a GHS-R1a agonist produces substantially more GH than either alone. The two most widely researched combinations:

CJC-1295 + Ipamorelin: The most studied combination in contemporary GH secretagogue research. CJC-1295’s sustained GHRHR engagement provides continuous somatotroph priming; Ipamorelin pulses provide GHS-R1a stimulation without cortisol co-activation. The result is robust, sustained GH elevation with twice-daily Ipamorelin administration amplifying the CJC-1295 GH bleed.

Sermorelin + Ipamorelin (or GHRP-6): Pulsatile combination — each injection produces a synergistically amplified GH pulse through dual receptor pathway activation, without the sustained elevation of CJC-1295. More physiological in pulse character; appropriate for pulsatile GH physiology research.

Quick Reference: Research Tool Selection

For studying the endogenous GH regulatory system / GH stimulation test: Sermorelin — most physiological GHRH stimulus.

For studying sustained GH axis elevation / chronic anabolic biology: CJC-1295 — infrequent dosing, sustained GH/IGF-1 elevation.

For studying clean GH pulses / sleep and recovery GH biology: Ipamorelin — selective, minimal off-target hormonal effects.

For studying the ghrelin axis / appetite / GI motility / full GHS-R1a pharmacology: GHRP-6 — complete ghrelin mimetic, not just GH secretagogue.

For maximum GH secretion / combination anabolic research: CJC-1295 + Ipamorelin — synergistic dual-pathway protocol.

Summary

The four major GH secretagogues — sermorelin, CJC-1295, Ipamorelin, and GHRP-6 — differ primarily in receptor target (GHRHR vs GHS-R1a), half-life (minutes to days), and selectivity (clean GH vs full ghrelin-axis pharmacology). Selecting the correct compound requires matching the research question to the compound’s specific pharmacological profile rather than treating them as interchangeable GH-raising tools. For UK GH axis researchers, understanding these distinctions is foundational to valid study design and interpretable results.